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a greater BRM increase at six months, whereas age, sex ratio,Cyclosporine bone remodeling effect prevents steroid osteope-
and plasma creatinine, PTH and 25 OH vitamin D were compa-nia after kidney transplantation.
rable and stable from months 3 through 24. The mean troughBackground. It is well established that prednisone above 7.5
level of cyclosporine for the first six months was positivelymg/day may induce osteopenia in association with decreased
correlated to osteocalcin and total alkaline phosphatase in-bone formation. In contrast, the effect of cyclosporine on bone
crease at six months, and both bone formation and resorptionremodeling and bone mineral density (BMD) is controversial.
marker increases were significantly correlated to the lumbarMultiple confounding factors explain this controversy, espe-
QCT Z score increase at 24 months.cially after renal transplantation.
Conclusions. Combined low-dose prednisone and cyclo-Methods. Fifty-two renal transplanted patients never ex-
sporine immunosuppression are associated with a stabilizationposed to aluminum while on dialysis were selected because
they had no rejection and no hypercalcemia for 24 months of BMD measured at all sites with DEXA 3 to 24 months after
while being treated with low dose prednisone/cyclosporine A renal transplantation and with a prevention of age-related loss
(daily dose at 10 mg and 4.8 mg/kg, respectively, beyond 3 of vertebral trabecular bone, as shown by the significant in-
months). Bone remodeling markers (BRMs; plasma osteocal- crease in lumbar spine QCT Z score. It is suggested that
cin, bone and total alkaline phosphatases for formation, and cyclosporine, together with the decrease of prednisone dosage
urinary pyridinolines for resorption) were sequentially mea- but independent of renal function, PTH, and vitamin D status,
sured together with plasma creatinine, intact parathyroid hor- contributes to a transient stimulation of bone remodeling at
mone (PTH) and 25 OH vitamin D and cyclosporine from day six months, which counterbalances the deleterious effect of
0 to 24 months. BMD was measured at 3, 6, 12, and 24 months prednisone on bone formation and BMD.
by quantitative computerized tomography (QCT) at the lum-
bar spine and by double-energy x-ray absorptiometry (DEXA)
at this site, as well as at the femoral neck, radius shaft, and
It is well established that long-term prednisone ther-ultradistal (UD) radius.
Results. Plasma concentrations of creatinine, PTH, and 25 apy above 7.5 mg/day may induce osteopenia because
OH vitamin D initially decreased and stabilized beyond three of decreased bone formation (in relationship to the de-
months at 137 mmol/L, 1.5 the upper limit of normal (ULN) crease in osteoblast differentiation and proliferation and
and 11 ng/mL, respectively. All BRM increased significantly
to increased apoptosis of osteoblasts and osteocytes) andabove the ULN at six months and then decreased. The BMD
an increased bone resorption (caused by secondary hy-Z score at three months was low at all sites measured by
DEXA and QCT. Follow-up measurements showed stability perparathyroidism induced by calcium malabsorption)
of absolute value and of Z score at all sites measured by DEXA. [1–4]. In contrast, the effect of cyclosporine on bone
A comparison of the lumbar QCT Z score, which was available remodeling is controversial. In vitro studies show thatin 42 patients at 3 and 24 months, showed an increase in 28
cyclosporine A inhibits resorption of organotypic boneand a decrease in 14, so that the increase for the whole group
cultures, whereas most in vivo animal studies [5, 6], withwas significant (P , 0.04). Compared with patients with a
decreased Z score, those with an increased Z score had signifi- the exception of those of Orcel et al [7] and Klein, Shaf-
cantly higher cyclosporine and lower prednisone dosages and fer, and Wolfe [8], show that cyclosporine induces an
accelerated high-turnover osteopenia by stimulating
T-cell secretion of cytokines like interleukin-1 and -6 [5].Key words: osteopenia, kidney transplant, bone remodeling, predni-
sone, cyclosporine. The clinical data on the bone effect of cyclosporine
in transplantation also support a stimulating effect onReceived for publication February 15, 1999
bone turnover because, in contrast to the precyclospor-and in revised form March 16, 2000
Accepted for publication May 12, 2000 ine era [4], bone formation and resorption markers are
increased at least transiently during the first year [9–12].Ó 2000 by the International Society of Nephrology
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Bone histopathological data have confirmed the con- METHODS
trast between the decreased bone formation observed 6 Patients
to 12 months after transplantation with prednisone 6 Seventy-nine patients received a cadaveric kidney al-
azathioprine treatment [13–15] and the stimulation of lograft and gave informed consent for measurement of
bone formation and resorption with cyclosporine 1 BMD and bone remodeling markers (BRMs) for two
prednisone treatment. The difference was not explained years. Twenty-seven patients were excluded because of
by variations in prednisone therapy, time after trans- menopause (5 patients), poor renal function (plasma
plantation, and renal function in a prospective compara- creatinine .200 mmol/L, 2 patients), acute rejection (14
tive study [15]. patients), diabetes (3 patients), and lack of data (3 pa-
In spite of the fact that cyclosporine is a glucocorticoid- tients). A total of 52 patients (42 men and 10 women)
sparing agent and may therefore protect against pred- was therefore included in this study. Their mean age 6
nisone-induced ostopenia, the net result of combined SD was 39 6 11 years. The causes of end-stage renal
therapy on bone mineral density (BMD) after renal failure were glomerulonephritis (22 cases) interstitial ne-
transplantation is not judged to be beneficial in most phritis (7 cases), polycystic kidney disease (10 cases),
studies, even though the decrease of BMD attenuates hereditary disease (8 cases), undetermined nephropathy
over the long-term [16–20]. The suspicion of a deleteri- (4 cases), and vascular nephropathy (1 case). The dura-
ous effect of cyclosporine on BMD is reinforced by the tion on dialysis was 12 6 6 months. During dialysis,
observation that in heart transplant patients treated with the patients were never exposed to aluminum in the
low-dose prednisone/cyclosporine, BMD decreases in as- dialysate, since reverse osmosis-treated water was used
sociation with increased osteocalcin and alkaline phos- or by the oral aluminum phosphate binders because of
exclusive use of CaCO3. The lack of aluminum exposurephatase levels [21, 22]. However, recent studies have
was confirmed by plasma aluminum values on mainte-shown that cyclosporine in monotherapy may have no
nance dialysis, which were always below 0.50 mmol/L.harmful effect [23–25] or even a beneficial effect on
Parent vitamin D and CaCO3 as phosphate binders wereBMD [26], as well as on trabecular bone volume assessed
prescribed before transplantation, but not afterward. Noon bone biopsy [27]. In the latter study, the disappear-
patient received ketoconazole or aluminum hydroxide.ance of heavy aluminum overload was a confounding
None complained of bone pain.issue, and multiple other factors may explain these dis-
crepancies: (1) heterogeneity in previous vitamin D de-
Immunosuppression
ficiency and hyperparathyroid bone diseases developed
Immunosuppressive therapy consisted of antithymo-during long-term dialysis and their variable regression
cyte globulin (ATG) from day 0 to day 10 (Thymoglo-rate after transplantation due to heterogenous renal graft
bulines Imtix Pasteur Merieux with initial dosage offunction; (2) population heterogeneity regarding other
1.25 mg/kg daily), cyclosporine A (Sandimmun Sandoz)osteopenia risk factors such as diabetes and postmeno-
started at day 0 (1 mg/kg/day) and increased to 8 mg/pausal status; (3) the heterogeneity in immunosuppres-
kg/day when ATG was discontinued. Cyclosporine dos-sive regimen and specifically in the glucocorticoid dose,
age was adjusted to achieve trough serum levels at 200which critical importance in early bone loss is well estab-
to 300 during the three first months and 150 to 200 ng/mL
lished [6, 13, 14]; (4) interference of other drugs, like
at one year. After a preoperative bolus of 500 mg of
ketoconazole, which decreases cyclosporine metabolism, methylprednisolone, oral prednisone was started at 1 mg/
potentiates prednisone effects, and decreases calcitriol kg/day and was progressively tapered to 0.5 mg/kg/day
synthesis [28]; and (5) heterogeneity in BMD measure- (1 month) and 10 mg/day after three months post-trans-
ments regarding technique, timing after transplantation, plantation (Table 1). Cyclosporine dosage was stable
and site [29]. during the first six months (7 to 6.5 mg/kg/day) and slowly
We herein report a prospective long-term follow-up decreased until two years after engraftment (to 4.8 mg/
(from 3 months to 2 years post-transplantation) of se- kg/day).
quential BMD measurements performed not only at the
Laboratory measurementslumbar spine [by absorptiometry and quantitative axial
computerized tomography (QCT)], but also at the radius Patients were studied on day 0 (just before surgery)
and femoral neck level (by absorptiometry only) in a and sequentially at 14, 30, 90, 180, and 365 days, and 24
population of 52 normocalcemic renal transplant pa- months after transplantation.
tients. These patients were selected to assess the effect Plasma concentrations of calcium, phosphorus, creati-
of low-dose prednisone combined with cyclosporine A, nine, total alkaline phosphatase activity, and urinary con-
without interference of the previously mentioned con- centrations of calcium, phosphate, and creatinine were
measured using standard techniques in the central labo-founding factors.
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Table 1. Immunosuppressive treatment
Day 14 Day 30 3 months 6 months 12 months 24 months
Cyclosporine dosage mg/kg/day 7.761 7.760.6 760.7 6.560.8 5.761 4.860.9
Cyclosporine trough levels ng/mL 149677 190685 246698 222686 194673 160651
Oral prednisone mg/day 52611 33610 1364 1060.8 1060.4 1060.4
Data are mean 6 SD of 52 patients.
ratory in our institution. Urinary pyridinolines were of variance was used to compare the two groups in which
measured by high-performance liquid chromatography lumbar QCT Z score increased or decreased from 3 to
[30, 31]. Serum intact parathyroid hormone (PTH) was 24 months for the various parameters of Table 5.
measured with the Chiron two-site immunochemilumi- Regression analysis was used to assess the associations
nometric assay [32]. Serum bone alkaline phosphatase between biochemical changes, BMD changes, and treat-
concentration was measured according to a previously ment. P , 0.05 was considered to indicate statistical
described method (Ostase kit from Hybritech Labora- significance. The results are expressed as mean 6 SD.
tory) [33]. Osteocalcin (bone GLA protein) was mea- Even though 52 patients were included in the study,
sured with an immunoluminometric method [34]. Plasma not all data are available at all points for each parameter.
25 OH vitamin D was measured by a competitive protein- Therefore, the number of patients for each comparison
binding assay [35]. or each correlation has been given.
Bone densitometry
RESULTSPatients were studied 3, 6, 12, and 24 months after
transplantation. BMD was measured using two tech- Bone mineral density
niques: dual-energy x-ray absorptiometry (DEXA) with Vertebral BMD measured with QCT was stable from
the Hologic QDR 2000 instrument (Hologic, Inc., Wal- three months to two years (when expressed in absolute
tham, MA, USA) and by quantitative computerized to- values) and was increased when expressed as Z scores
mography (QCT) (General Electric). (from 21.37 to 21.19; Table 2). This increase between
Dual-energy x-ray absorptiometry measured the ante- 3- and 24-month Z scores was significant by the paired
roposterior BMD of the second, third, and fourth lumbar Wilcoxon test (0.18, P , 0.04). Paired data were available
vertebrae (trabecular bone), as well as the BMD at the only in 42 patients and showed an increase in 28 and a
radius ultradistal (UD) site (where bone is mainly trabec- decrease in 14 patients. The vertebral BMD Z score
ular) and at its shaft (the junction between distal third measured by DEXA increased, but not significantly.
and proximal two thirds) where bone is mainly cortical. Vertebral Z scores obtained with QCT and DEXA were
BMD was also measured by DEXA at the femoral neck positively correlated (r 5 0.76, P , 0.0001).
(mixed bone). Quality control of the machine was per- Bone mineral density absolute absorptiometric data
formed by daily scanning of an anthropomorphic phan-
at the UD radius, radius shaft, and femoral neck were
tom supplied by the manufacturer. The interday in vitro
stable from three months to two years. At three-monthsvariability was 0.4%. DEXA BMD is an areal density
post-transplantation, the mean Z score was negative atand is expressed either in absolute value in grams of
all sites (20.95, 20.62, and 21.34) and did not changehydroxyapatite divided by the projected area in square
significantly for two years.centimeters (g/cm2) or by the number of standard devia-
tions from the mean of age- and sex-matched controls Biochemical determinations
(Z score) [36].
Table 3 shows that mean serum creatinine concentra-Quantitative computerized tomography was used to
tion significantly decreased from day 0 to day 14 andmeasure trabecular mineral density of L2-L3-L4 lumbar
then remained constant around 137 mmol/L. The plasmavertebrae. QCT BMD is a true volumetric density ex-
total calcium concentration was always in the normalpressed in absolute value in mg/cm3. It is also expressed
range, but presented a slight and transient decrease atin Z score, the normal mean of lumbar QCT BMD being
days 14 to 30 and then stabilized after six months atgiven by the following equations [37]: for men, 225 2
2.46 mmol/L. Plasma phosphate rapidly decreased to the0.62 3 age; and for women: 26.1 1 13.8 3 age 2 0.317 3
lower limit of normal at days 14 and 30 and then stabi-age2 1 0.00197 3 age3.
lized after six months to approximately 1.1 mmol/L. The
Statistical analysis mean serum concentration of intact PTH decreased from
184 pg/mL on day 0 to 96 pg/mL at day 14, and stabilizedThe Wilcoxon matched-pairs test was used to compare
chronological changes in the same whole group. Analysis after six months at 87 pg/mL, corresponding to 1.5-fold
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Table 2. Bone mineral density from 3 months to 2 years post-transplantation
Difference
Measurement method and sites Unitsa 3 months 6 months 1 years 2 years 24–3 months
Quantitative computerized tomography
Vertebra (L2-L3-L4) mg/cm3 122.6633 122.5635 125.13631 123.7628
Z score 21.3761.09 21.3661.19 21.2960.99 21.1961.03 10.18b
Dual x-ray absorptiometry
Vertebra L2-L3-L4 (frontal absorption) g/cm2 0.9360.2 0.9160.1 0.9360.1 0.9460.1
Z score 21.4061.4 21.4261.3 21.4161.2 21.3561.16 10.05
Ultradistal radius g/cm2 0.4460.1 0.4260.6 0.4260.1 0.41560.1
Z score 20.9561.4 2161.1 2161.2 21.161.4 20.15
Radius shaft g/cm2 0.7260.1 0.7460.1 0.7560.1 0.7560.1
Z score 20.6261 20.661.1 20.5861 20.5361.2 10.09
Femoral neck g/cm2 0.7460.1 0.7160.1 0.7460.1 0.7560.1
Z score 21.3461.2 21.5660.9 21.3960.9 21.2260.9 10.12
Data are mean 6 SD of 52 patients.
a mg/cm3 and g/cm2 mean milligram and gram equivalent of hydroxyapatite
b None of the measurements after 3 months significantly differs from that at 3 months at the exception of the lumbar QCT Z score at 3 and 24 months for which
paired Wilcoxon test showed a significant increase (P , 0.04)
Table 3. Follow-up of plasma creatinine, calcium, phosphate and intact parathyroid hormone (PTH)
Plasma concentration
normal range Day 0 Day 14 Day 30 3 months 6 months 12 months 24 months
Creatinine 70–120 lmol/L 8006200 145681b 121635 128630 137630 137630 137625
Calcium 2.2–2.6 mmol/L 2.5460.3 2.2760.2b 2.3360.2 2.4660.1 2.4760.1c 2.4660.2 2.4560.1
Phosphate 0.7–1.3 mmol/L 1.5760.6 0.8760.2b 0.7660.2 0.9860.2 1.0860.2c 1.1760.2 1.1360.2
Intact PTH 10–55 pg/mL 1846153 96655a 122679 92646 87641 94640 82643
Plasma 25 OH vitamin D
10–40 ng/mL 18612 11.3610a 1165 1166 15.369 10.266 12.567
Data are mean 6 SD. None of the changes is significant when comparing 6 months with 24 months
a P , 0.01, bP , 0.001, comparison of Day 0 with Day 14
c P , 0.001, comparison of Day 14 to 6 months
Table 4. Follow-up of the bone remodeling markers
Markers normal range Day 0 Day 14 Day 30 3 months 6 months 12 months 24 months
Markers of bone formation
Bone alkaline phosphatase
3.2–20.4 lg/L 12.569.4 11.369.7 16.969.7 21.7610.4 26.8611.9c 18.569.1 14.367.1e
Total alkaline phosphatase
40–120 IU/L 84657 72648a 86646 104652 119661c 93636 74626e
Osteocalcin (or bone GLA
protein) 4–12 ng/mL 28620 7611a 766 1369 20613c 21617 1468d
Markers of bone resorption
Urinary deoxypyridinoline
3–12 lmol/mol creatinine 9.365.7 9.466.4 9.464.6 12.866.7b 10.665.1 965.4e
Urinary pyridinoline
15–50 lmol/mol creatinine 51626 51629 50619 56625 45617 34624e
Data are mean 6 SD.
a P , 0.001, comparison of Day 0 to Day 14
b P , 0.01, c P , 0.001, comparison of Day 14 to 6 months
d P , 0.01, e P , 0.001, comparison of 6 months to 24 months
the upper limit of normal (Table 3). Plasma 25 OH vita- not in bone alkaline phosphatase. These markers of bone
formation showed a progressive increase up to sixmin D levels decreased significantly from day 0 to day
14 (from 17 to 11 ng/mL) and then remained stable up months, starting from day 30 for total and bone alkaline
phosphatase and from month 3 for osteocalcin. After sixto 24 months after transplantation.
Table 4 shows the absolute values of the BRMs during months, these markers progressively decreased until two
years, with the exception of osteocalcin, which decreasedfollow-up. At day 14, there was a significant decrease in
plasma osteocalcin and total alkaline phosphatase, but only after 12 months. Figure 1 shows the data expressed
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SD) and sex ratio (11/3 vs. 23/5 males/females) did not
differ between the two groups. Plasma concentrations
of creatinine, PTH, and plasma 25 OH vitamin D were
comparable in both groups at 3, 6, 12, and 24 months.
The levels of BRMs at six months were higher in the
patients with an increased Z score at 24 months, but the
difference was significant only for pyridinolines and total
alkaline phosphatase.
Correlatives studies
The mean daily dose of prednisone at three months
was significantly negatively correlated to the lumbar
QCT score changes between 3 and 6 or 24 months (r 5
20.37, N 5 43, P , 0.02).
Mean trough cyclosporine levels for the first six
months were significantly correlated to osteocalcin (0.48,
N 5 28, P , 0.01; Fig. 2) and to total alkaline phosphatase
increases from 0.5 to 6 months (r 5 0.40, N 5 25, P ,
0.05), but not to the pyridinoline increases.
Table 6 shows that the increases of all remodeling
Fig. 1. Follow-up of bone remodeling markers (BRMs) (A) and treat- markers between 0.5 and 6 months were correlated to
ment (B). Symbols are: (j) parathyroid hormone; (h) osteocalcin; the changes of lumbar QCT Z score between 3 and 24
(m) total alkaline phosphatase; (n) bone alkaline phosphatase; (s)
months.pyridinoline; (d) Deoxypyridinoline. Black boxes represent steroid doses.
DISCUSSION
We evaluated BMD in a highly selected renal trans-in percentage of the upper limit of normal; at six months,
plant population to discard most of the recognized con-bone alkaline phosphatase and osteocalcin levels were
founding factors. We found that low-dose prednisoneabove the upper limit of normal. At this point, the dose
and cyclosporine therapy is associated with a stabiliza-of cyclosporine was still high (6.5 ng/kg/day), whereas
tion of BMD measured by DEXA at all sites beyondthe dose of prednisone had been decreased to 10 mg/
three months. An increase of the lumbar QCT Z scoreday. The decrease in the bone formation markers to
suggests prevention of age-related loss of vertebral tra-normal levels at two years occurred, while the dose of
becular bone. The fact that only the lumbar QCT Z scorecyclosporine decreased to 4.8 ng/kg/day and that of pred-
shows an increase between 3 and 24 months but not thenisone remained stable at 10 mg/day.
DEXA Z score may be explained by the larger surfaceThe markers of bone resorption were measured only in
of trabecular bone involved in bone remodeling than24-hour urine specimen and therefore were not available
that of the cortical bone. Schober et al have indeedbefore transplantation. Deoxypyridinolinuria was 80%
evaluated that an increase of 25 mm of bone thicknessof the upper limit of normal, and pyridinolinuria was at
on the entire trabecular surface would result in a 30 tothis limit during the three first months. Both increased
40% increase of mineralized bone volume, whereas theslightly above normal, but only at six months, and then
same thickness increase at the entire endosteal surfacedecreased to normal. The increase at six months was
would result in only a 3% increase of mineralized corticalsignificant only for deoxypyridinoline.
bone [38]. Indeed, QCT used in this study measured aIt is noteworthy that plasma intact PTH and 25 OH
true volumetric density of trabecular bone, and its resultsvitamin D levels stabilized between day 14 and two years,
are expressed in mg of calcium per cm3, whereas DEXAwhile the markers of bone remodeling transiently in-
measures only an areal density related to the calciumcreased above normal at six months.
content not only of the trabecular bone, but also of two
Factors connected with vertebral BMD changes corticals.
This favorable effect was observed while all BRMsTable 5 shows that lumbar QCT Z scores increased
in 28 patients and decreased in 14. Patients whose Z transiently increased to values at/or above normal at six
months. A comparison of the 28 patients whose lumbarscore increased had significantly lower prednisone and
higher cyclosporine doses (therefore, higher cyclosporine/ QCT Z scores increased to the 14 patients whose Z
scores decreased showed that lower prednisone andprednisone dosage ratio) than those in whom Z scores
decreased. Age (35 6 8 vs. 40.7 6 11.6 years, mean 6 higher cyclosporine dosages were the sole distinctive
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Table 5. Comparison of treatment, plasma concentrations of creatinine, PTH and vitamin D and of bone remodeling markers in patients
with increasing or decreasing lumbar QCT Z score between 3 and 24 months post-transplantation
Lumbar QCT Z score
Increasing (N 5 28) Decreasing (N 5 14)
Parameters (1 0.8560.70) (20.7760.69) P
Treatment dosage for 3–24 months
Prednisone mg/day 10.560.5 11.261.3 0.02
Cyclosporine mg/kg/day 6.7060.5 6.3560.6 0.05
Ratio cyclosporine/prednisone 0.5960.07 0.5360.08 0.02
Plasma creatinine lmol/L
3 months 124625 133635 NS
6 months 134627 143632 NS
12 months 134629 141632 NS
24 months 137625 143625 NS
PTH status pg/mL
3 months 93652 91636 NS
6 months 92646 80634 NS
12 months 96645 88633 NS
24 months 85648 81634 NS
Plasma 25 OH vitamin D ng/mL
3 months 1066 1366 NS
6 months 1568 16610 NS
12 months 1166 967 NS
24 months 1265 1166 NS
Bone remodeling marker at 6 months
Urinary deoxypyridinoline lmol/mmol creatinine 14.6673 8.563.3 0.01
Urinary pyridinoline lmol/mmol creatinine 62625 40611 0.01
Total alkaline phosphatase IU/L 174647 109629 0.01
Bone alkaline phosphatase lg/L 28611 22611 NS
Osteocalcin ng/mL 22614 16611 NS
Data are mean 6 SD. ANOVA was used to determine P values. Abbreviations are: PTH, parathyroid hormone; QCT, quantitative computerized tomography.
characteristic between the two groups. The groups were
comparable for age, sex ratio, and plasma concentrations
of creatinine, PTH, and 25 OH vitamin D for 3 to 24
months after transplantation. At six months, patients
with an increased QCT Z score had higher levels of
urinary pyridinolines and plasma total alkaline phospha-
tase. The mean trough cyclosporine level for the first six
months correlated to the increase at six months of the
bone formation markers, whereas increases in bone for-
mation and resorption markers correlated with the lum-
bar QCT Z score increase at 24 months.
Although we did not have a control group with a
comparable dose of prednisone and a different dose of
cyclosporine, all of these comparisons and correlations
suggest that cyclosporine contributed to the transient
increase of bone formation, independently of lowering
the prednisone dosage. Indeed, the prednisone dose was
still supraphysiologic and in the range expected to de-
crease osteoblast differentiation and proliferation [2].
Thus, the elevation of alkaline phosphatase and osteocal-
cin above normal cannot be explained solely by a decrease
in factors inhibiting bone formation (such as prednisone,
a uremic factor inhibiting osteoblasts, or aluminum over-
load). Stability of renal function excludes an increase of
osteocalcin levels simply due to decreased urinary excre-
Fig. 2. Correlation of plasma osteocalcin increase at six months and
tion. Stability of plasma PTH and 25 OH vitamin D levelsmean trough level of cyclosporine during the first six months (P 5 0.01;
r 5 0.48; N 5 28). excludes hyperparathyroidism worsening and changes in
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Table 6. Correlations of lumbar spine QCT Z score increase at 24 months and remodeling factor changes between 0.5 and 6 months
Z score change period Remodeling marker 6–0.5 months r N P
24–3 months Osteocalcin 10.54 20 0.01
Bone alkaline phosphatase 10.40 40 0.01
Total alkaline phosphatase 10.80 18 0.0001
Deoxypyridinoline 10.34 37 0.04
Pyridinoline 10.30 38 0.06
vitamin D status as explanations for the increase of bone control group. However, the interpretation of these stud-
ies is confounded by important issues: severe hyperpara-remodeling parameters.
Because cyclosporine increased biochemical and his- thyroidism in that of Torregrosa et al [23], improvement
of the bone aluminum overload in that of Briner et altologic bone formation markers in animal [7, 8] and
clinical studies [9, 11, 12, 15], and the cyclosporine mean [27], and lack of information on pretransplant renal os-
teodystrophy and on prevalence of methylprednisolone-trough level for the first six months in this study corre-
lated to the six-months increase in osteocalcin and total treated rejections in that of Parry et al [24]. Most infor-
mative was the prospective study by Aroldi et al, whichalkaline phosphatase, we suggest that cyclosporine was
responsible for the increase in the bone formation mark- showed that lumbar DEXA Z scores were significantly
greater in 13 patients with cyclosporine monotherapyers in this study.
The suggestion that cyclosporine contributed to the than in 20 patients receiving cyclosporine 1 prednisone
and in 20 patients on triple therapy, despite very largebeneficial effect on BMD comparatively to age- and sex-
matched control by stimulating preferentially bone for- standard deviations [26]. This study is therefore in agree-
ment with our study showing that cyclosporine with low-mation is further supported by the observation that the
lumbar QCT Z score increases at 24 months were corre- dose prednisone can prevent the age-related trabecular
bone loss before two-years post-transplantation and sup-lated with all BRM increases at six months, while in
contrast, prednisone at 10 mg/day would be expected to ports a proper bone-sparing effect of cyclosporine.
The clinical data on bone effect of cyclosporine inincrease bone resorption and to decrease bone formation
and BMD [2, 3]. The lumbar QCT Z score increase, in other organ transplantations are generally interpreted as
evidence for a deleterious effect on BMD of cyclosporinespite of stimulation of both formation and resorption, is
not surprising. It has been also documented during the bone hyper-remodeling effect, but again are clouded by
numerous confounding factors. In heart transplantation,prevention of bone loss in patients with therapeutical
estrogen deficiency for endometriosis [39] or glucocorti- previous smoking, prolonged physical inactivity, and
high-dose cyclosporine induced nephrotoxicity are prob-coid-induced osteoporosis [40] by daily injection of PTH
(1-34). The principal mechanism of this anabolic effect lematic. In the study by Thiebaud et al, high-turnover
bone loss was related to cyclosporine or hyperparathy-on bone of intermittent PTH administration is the pre-
vention of the osteoblast and osteocyte apoptosis [1]. roidism [21]. Indeed, severe bone loss at six months oc-
curred with an increase of osteocalcin, whereas PTHInterestingly, while Movsowitz et al have stressed the
osteopenic effect of high bone turnover in rats induced levels stabilized at lower level after month 2, but the
lack of significant BMD increase at 12 months in spiteby cyclosporine, they have also reported that combined
therapy with cyclosporine and cortisone acetate stabi- of corticotherapy discontinuation was related to an in-
crease of plasma creatinine, PTH, and total alkalinelized their bone mass [41]. However, the rat model for
osteopenia is not a good model for human glucocorticoid phosphatase, suggesting a role of hyperparathyroidism
induced by renal insufficiency caused by cyclosporineosteoporosis since glucocorticoids stimulate bone forma-
tion in rat. toxicity.
After liver transplantation with combined prednisoneIn clinical renal transplantation, most long-term BMD
data beyond two years document an attenuation of the and cyclosporine therapy, Vedi et al showed by histomor-
phometry an increase in bone turnover in the first threebone loss in patients treated with cyclosporine 1 predni-
sone 6 azathioprine. This loss becomes parallel to the post-transplant months without a significant disruption
of cancellous bone [42]. They further speculated, withoutage-related bone loss [18, 20]. As the same is observed
on the very late, after 80- to 120-months post-trans- other long-term data, that this increase in bone remodel-
ing predisposes to trabecular penetration and decreasedplantation, in patients treated with prednisone and aza-
thioprine alone [25], this long-term favorable outcome bone strength.
In hemopoietic stem cell transplantation, Eberling etmay only reflect the decrease in prednisone dose. This
possibility stresses the contribution of recent controlled al have suggested that cyclosporine played a role in bone
loss, but only on the basis of correlation between BMDstudies with a cyclosporine monotherapy group and a
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